70653

Evaluation of urinary isoflavones and climacteric symptomatology in menopausal women

Favorite this paper

In the menopause, the decline in the secretion of sex hormones converge to the onset of vasomotor and urogenital symptoms. This study evaluated the intensity of climacteric symptomatology related to aglycones presence in urine in 60 women aged 40 to 60 years, in amenorrhea for at least 12 months and current presence of symptoms of estrogen deprivation. They answered the Menopause Rating Scale questionnaire, used to assess the intensity of climacteric symptoms, and had their urine analyzed for the presence of isoflavones aglycones coming from the diet (genistein and daidzein) by Gas chromatography/mass spectrometry, with analytes identified by the mass load (m/z), retention time and spectrum comparable to the standard. The results showed that 3% of the women presented mild climacteric symptoms, 27% moderate and 70% severe, in ascending order hot flushes, irritability and sleep disturbances reached the highest intensity indexes. Isoflavone genistein was detected in the urine of 38 women (63%) and daidzein was found in 3 (5%) women, in some quantity, 2 (3%) women presented both aglycones and 17 participants (28%) had no aglycones detected in urine. Women with urinary aglycones that report having vasomotor symptoms such as those of major importance could benefit from the use of isoflavones to contain them, with greater benefit of these phenolics in the reduction of heat waves, which are generally those of greater relevance and culminate in irritability and insomnia or intermittent sleep. Women where the presence aglycones is not detected, that have severe symptoms of menopause or do not report vasomotor symptoms as the most important, complaining mostly of urogenital and sexual problems, would not have so many benefits with the use of isoflavones, being the conventional hormone therapy indicated if there is no contraindication. Isoflavones are indicated to use in women that metabolise this compounds, producing higher activity metabolites.